{"id":"NCT00391274","sponsor":"Eli Lilly and Company","briefTitle":"Chemotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC)","officialTitle":"Phase 3 Study of Pemetrexed Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Had Prior Chemotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-10","primaryCompletion":"2008-12","completion":"2010-06","firstPosted":"2006-10-23","resultsPosted":"2010-03-30","lastUpdate":"2011-04-12"},"enrollment":211,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Non-Small Cell Lung Cancer"],"interventions":[{"type":"DRUG","name":"pemetrexed","otherNames":["LY231514","Alimta"]},{"type":"DRUG","name":"docetaxel","otherNames":[]}],"arms":[{"label":"Pemetrexed","type":"EXPERIMENTAL"},{"label":"Docetaxel","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to compare the efficacy and toxicity of pemetrexed and docetaxel administered on a 3-weekly schedule in the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have had prior chemotherapy.","primaryOutcome":{"measure":"Overall Survival","timeFrame":"baseline to date of death from any cause (up to 24 months after study enrollment); amendment (up to 30 months after study enrollment)","effectByArm":[{"arm":"Pemetrexed","deltaMin":11.7,"sd":null},{"arm":"Docetaxel","deltaMin":12.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.4921"},{"comp":"OG000 vs OG001","p":"0.9256"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":7,"countries":["China"]},"refs":{"pmids":["24342300","23182660"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":106},"commonTop":["Fatigue","Anorexia","Dyspnoea","Cough","White blood cell count decreased"]}}